Inversago
Acquired
Developing next-generation CB1 blockade therapies for metabolic disease.
- Headquarters
- Montreal
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Website
- inversago.com
- Total Funding
- $112.0M
- Last Round
- $70.0M Series COct 2022
About
Inversago Pharma specialized in CB1 receptor blockade therapies for metabolic disorders. Acquired by Novo Nordisk in August 2023.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account